Longmen Capital

Kaidi Medical is a developer of tumor immunotherapy drugs.

Crystal Egg is a biopharmaceutical company dedicated to the independent research and development of first in class innovative new drugs for major diseases such as depression, chronic kidney disease, pain and rare diseases, as well as providing customers with high-quality products and R&D services in membrane protein-related fields. enterprise. The company has built membrane protein expression and purification platforms, structural biology platforms, pharmacology platforms and nanobody screening platforms, and has rich R&D pipelines in the fields of ion channels and GPCRs.

Qi Xiangdong, founder of Qiyu Bio, said: “Innovation is the starting and future of Qiyu Bio, and it is the core driving force of enterprise development. Qiyu Bio will use the first-class antibody technology platform to build superior biopharmaceutical pipelines and explore the field of biotherapy. A big breakthrough. With the development and improvement of the company, Qiyu will have core competitiveness in more fields.

Hopstem is a Hangzhou-based pharmaceutical company, engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering.

Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical genetic diagnosis services for hereditary ophthalmology patients.

Lyvgen Biopharma is a cross-linking-dependent antibody platform. The company also provides tumor immune agonistic antibody, local activation of the tumor microenvironment, and synthetic biology engineering services.

Ractigen is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.

Deyi Sunshine Biotechnology (Beijing) Co., Ltd. was established in April 2013 in Zhongguancun Biomedical Park, Haidian District, Beijing. In March 2014, it established a subsidiary Deyang Biotechnology in Gu'an Emerging Industry Demonstration Zone, Langfang City, Hebei Province. (Gu'an) limited liability company. Deyi Sunshine is a biotechnology company focused on developing a new class of drugs. The company has a world-leading innovative biopharmaceutical research and development platform. Based on the analysis of the industry and relying on the unique core technology-Sunshine Protein Optimization Platform, the company has successfully developed Pegelan (a kind of innovation for treating chronic norovirus infection in patients with immune deficiency). Orphan drug), Sporphene (an innovative orphan drug for minimally invasive repair of articular cartilage injury), Perox (an innovative orphan drug for the treatment of stubborn gout with visible crystals) and Defenfen (for the treatment of lupus erythematosus) A class of innovative drugs for renal failure and uremia) and many other world-leading research results. The research varieties all have independent intellectual property rights of the active ingredients of the drug. It is expected that the future listing will not only bring good news to the patients with rare diseases in the world, but also hope to expand into other indications and become a major innovative product. All the staff of the company adhere to the tenet of “Deze human beings, benefit the country and the people, and the healthy people”. We have the entrepreneurial spirit of “independent innovation and courage to open up” and make unremitting efforts to build China's first-class bio-pharmaceutical company!

Sirnaomics is a clinical-stage biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology. The RNAi technology is used to discover and develop novel therapeutics with a focus on oncology, anti-fibrotic therapeutics, and viral infection. Its proprietary Polypeptide Nano-Particle (PNP) technology is used for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver. Sirnaomics was founded by Patrick Y. Lu and David M. Evans in 2007 and is based in Gaithersburg, Maryland.

CF PharmTech was founded in 2007, it is a fully independent, dynamic, integrated, specialty pharmaceutical company focused on the development and manufacturing of products for the treatments of asthma, COPD and allergic rhinitis for the global market. Its mission is to develop high-quality and affordable medicine to help patients achieve effective management care for their respiratory diseases. The headquarters is located in the lakeside of the Caohu District of Suzhou, Jiangsu Province, with many very convenient transportation options available. It only takes thirty minutes by train to Shanghai and four hours by train to Beijing.

LeapMed biopsy kits for transducers cover applications for abdominal, superficial, cardial, endo, and 3D. It is a manufacturer and supplier of ultrasound biopsy kits. LeapMed's independently created disposable ultrasonic intervention consumable items include precisely positioned disposable ultrasonic puncture racks, disposable biopsy needles, disposable puncture needles, nerve block needles, and other devices.

SmartNuclide is dedicated to the discovery, manufacture, and marketing of nuclear medicine diagnostic and therapeutic pharmaceuticals. The company established a number of research and development pathways for radiopharmaceutical medications, including recombinant proteins, imaging, and radiotherapeutic pharmaceuticals.

SiBionic develops and monetizes artificial intelligence for medical imaging and implantable medical devices. They are working on technologies including implanted retinal electrical stimulators, continuous glucose monitoring, sugar reticulum screening, gastric cancer screening, health management, managing chronic diseases, screening for diseases, diagnosing diseases, and treating diseases.